Schering buys Diatide to enter radiopharmaceuticals
This article was originally published in Clinica
Executive Summary
German company Schering is to extend its imaging business into radiopharmaceuticals through the acquisition of US company Diatide for around $120 million. Schering is offering to pay $9.50 per share for Diatide through its own US subsidiary, Schering Berlin.